These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23668372)

  • 1. Modification of pharmacological activity of nebivolol due to Maillard reaction.
    Patil DD; Patil CR
    Pharm Dev Technol; 2013; 18(4):844-51. PubMed ID: 23668372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compatibility studies of acyclovir and lactose in physical mixtures and commercial tablets.
    Monajjemzadeh F; Hassanzadeh D; Valizadeh H; Siahi-Shadbad MR; Mojarrad JS; Robertson TA; Roberts MS
    Eur J Pharm Biopharm; 2009 Nov; 73(3):404-13. PubMed ID: 19631740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea-Lactose Interaction Study: In Silico and In Vitro Evaluation.
    Bachchhao KB; Patil RR; Patil CR; Patil DD
    AAPS PharmSciTech; 2017 Nov; 18(8):3034-3041. PubMed ID: 28500485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Maillard reaction of bisoprolol fumarate with various reducing carbohydrates.
    Szalka M; Lubczak J; Naróg D; Laskowski M; Kaczmarski K
    Eur J Pharm Sci; 2014 Aug; 59():1-11. PubMed ID: 24746680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats.
    Sacco G; Evangelista S; Criscuoli M; Goso C; Bigioni M; Binaschi M; Manzini S; Maggi CA
    Eur J Pharmacol; 2005 Mar; 511(2-3):167-74. PubMed ID: 15792785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine.
    Wirth DD; Baertschi SW; Johnson RA; Maple SR; Miller MS; Hallenbeck DK; Gregg SM
    J Pharm Sci; 1998 Jan; 87(1):31-9. PubMed ID: 9452965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of evidence that nebivolol is a β₃-adrenoceptor agonist.
    Frazier EP; Michel-Reher MB; van Loenen P; Sand C; Schneider T; Peters SL; Michel MC
    Eur J Pharmacol; 2011 Mar; 654(1):86-91. PubMed ID: 21172342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with a highly selective β₁ antagonist causes dose-dependent impairment of cerebral perfusion after hemodilution in rats.
    Hu T; Beattie WS; Mazer CD; Leong-Poi H; Fujii H; Wilson DF; Tsui AK; Liu E; Muhammad M; Baker AJ; Hare GM
    Anesth Analg; 2013 Mar; 116(3):649-62. PubMed ID: 23400988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between the sympatholytic action of nebivolol and hypotension.
    Ward JE; Coles P; Cox H; Eisenhofer G; Angus JA
    J Cardiovasc Pharmacol; 1992 Jul; 20(1):115-24. PubMed ID: 1383620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
    Fang Y; Nicol L; Harouki N; Monteil C; Wecker D; Debunne M; Bauer F; Lallemand F; Richard V; Thuillez C; Mulder P
    J Mol Cell Cardiol; 2011 Aug; 51(2):168-76. PubMed ID: 21640121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol.
    Varagic J; Ahmad S; Brosnihan KB; Habibi J; Tilmon RD; Sowers JR; Ferrario CM
    Am J Nephrol; 2010; 32(6):557-66. PubMed ID: 21042014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker.
    Gao Y; Vanhoutte PM
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):16-21. PubMed ID: 21283024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No evidence of nitrate tolerance caused by nebivolol.
    Stoschitzky K; Stoschitzky G; Pieske B; Wascher T
    Ther Adv Cardiovasc Dis; 2014 Apr; 8(2):40-4. PubMed ID: 24532547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory Notes on Impact of Excipients on Drug Products and the Maillard Reaction.
    Chowdhury DK; Sarker H; Schwartz P
    AAPS PharmSciTech; 2018 Feb; 19(2):965-969. PubMed ID: 28948567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
    Ignarro LJ
    Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of nebivolol.
    Janssens WJ
    J Pharm Belg; 1992; 47(4):323-7. PubMed ID: 1357130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical effects of nebivolol on wounds in diabetic rats.
    Gulcan E; Kuçuk A; Çayci K; Tosun M; Emre H; Koral L; Aktan Y; Avsar U
    Eur J Pharm Sci; 2012 Sep; 47(2):451-5. PubMed ID: 22820030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.
    Cheymol G; Poirier JM; Carrupt PA; Testa B; Weissenburger J; Levron JC; Snoeck E
    Br J Clin Pharmacol; 1997 Jun; 43(6):563-70. PubMed ID: 9205815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of nebivolol, atenolol and propranolol on in vivo cardiovascular and metabolic responses to isoproterenol in dogs.
    Bowden CR; Marchione CS
    J Pharmacol Exp Ther; 1989 Nov; 251(2):599-605. PubMed ID: 2572694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compatibility of chewing gum excipients with the amino acid L-cysteine and stability of the active substance in directly compressed chewing gum formulation.
    Kartal A; Björkqvist M; Lehto VP; Juppo AM; Marvola M; Sivén M
    J Pharm Pharmacol; 2008 Sep; 60(9):1131-8. PubMed ID: 18718115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.